Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group

BACKGROUND: To evaluate the value of KRAS codon 13 mutations in patients with advanced colorectal cancer (advanced CRC) treated with oxaliplatin and fluoropyrimidines. METHODS: Tumor specimens from 201 patients with advanced CRC from a randomized, phase III trial comparing oxaliplatin/5-FU vs. oxali...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinacher-Schick, Anke, Schulmann, Karsten, Modest, Dominik P, Bruns, Nina, Graeven, Ulrich, Jaworska, Malgorzata, Greil, Richard, Porschen, Rainer, Arnold, Dirk, Schmiegel, Wolff, Tannapfel, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442969/
https://www.ncbi.nlm.nih.gov/pubmed/22876876
http://dx.doi.org/10.1186/1471-2407-12-349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442969/
https://www.ncbi.nlm.nih.gov/pubmed/22876876
http://dx.doi.org/10.1186/1471-2407-12-349

Ejemplares similares